Sugi Predict

Sugi Predict / Compounds / SCHEMBL447251

SCHEMBL447251

SCHEMBL447251

Nc1nc(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1C=CBr

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TK1 P04183 2/20 0.64
▸ CYP1A2 P05177 1/20 0.64
▸ CYP3A4 P08684 1/20 0.64
▸ TSHR P16473 1/20 0.64
▸ BLM P54132 1/20 0.64
▸ PMP22 Q01453 1/20 0.64
▸ NPSR1 Q6W5P4 1/20 0.64
▸ DNMT1 P26358 8/20 0.57
▸ ADRB1 P08588 1/20 0.57
▸ DNMT3B Q9UBC3 3/20 0.50
▸ LMNA P02545 2/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ PNP P00491 1/20 0.45
▸ TP53 P04637 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ PDE4D Q08499 1/20 0.45
▸ PDE3A Q14432 1/20 0.45
▸ RXFP1 Q9HBX9 1/20 0.45
▸ FPR2 P25090 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL447250 1.00 TK1 (0.64) TK1CYP1A2CYP3A4TSHRBLM
SCHEMBL447249 1.00 TK1 (0.64) TK1CYP1A2CYP3A4TSHRBLM
SCHEMBL5982338 1.00 TK1 (0.64) TK1CYP1A2CYP3A4TSHRBLM
SCHEMBL6359874 1.00 TK1 (0.64) TK1CYP1A2CYP3A4TSHRBLM
SCHEMBL9803687 0.91 DNMT1 (0.57) TK1CYP1A2CYP3A4TSHRBLM
SCHEMBL9803679 0.91 DNMT1 (0.57) TK1CYP1A2CYP3A4TSHRBLM
SCHEMBL5982360 0.91 DNMT1 (0.57) TK1CYP1A2CYP3A4TSHRBLM
SCHEMBL9803693 0.91 DNMT1 (0.57) TK1CYP1A2CYP3A4TSHRBLM
SCHEMBL2293952 0.89 DNMT1 (0.57) TK1CYP1A2CYP3A4TSHRBLM
SCHEMBL5982097 0.89 DNMT1 (0.57) TK1CYP1A2CYP3A4TSHRBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120219602-A1 METHODS FOR TREATING HERPES VIRUS INFECTIONS NANOBIO CORPORATION 2012-08-30 — — US claimed
EP-2280690-A2 METHODS FOR TREATING HERPES VIRUS INFECTIONS Nanobio Corporation (US) 2011-02-09 — — EP claimed
US-20100075914-A1 METHODS FOR TREATING HERPES VIRUS INFECTIONS NANOBIO CORPORATION 2010-03-25 — — US claimed
WO-2009129470-A2 METHODS FOR TREATING HERPES VIRUS INFECTIONS NANOBIO CORPORATION (US) 2009-10-22 — — WO claimed
US-4382925-A VIRICIDES, ESPECIALLY AGAINST HERPES VIRUS THE UNIVERSITY OF BIRMINGHAM (GB) 1983-05-10 — — US claimed
WO-2013130535-A1 TOPICAL DELIVERY OF HORMONAL AND NON HORMONAL NANO FORMULATIONS, METHODS OF MAKING AND USING THE SAME NEWGEN BIOPHARMA CORPORATION (US) 2013-09-06 — — WO disclosed
US-20130224268-A1 TOPICAL DELIVERY OF HORMONAL AND NON HORMONAL NANO FORMULATIONS, METHODS OF MAKING AND USING THE SAME NEWGEN BIOPHARMA CORP. (US) 2013-08-29 — — US disclosed
US-20120219602-A1 METHODS FOR TREATING HERPES VIRUS INFECTIONS NANOBIO CORPORATION 2012-08-30 — — US disclosed
US-20120064136-A1 ANTI-AGING AND WRINKLE TREATMENT METHODS USING NANOEMULSION COMPOSITIONS NANOBIO CORPORATION 2012-03-15 — — US disclosed
EP-2280690-A2 METHODS FOR TREATING HERPES VIRUS INFECTIONS Nanobio Corporation (US) 2011-02-09 — — EP disclosed
US-20100075914-A1 METHODS FOR TREATING HERPES VIRUS INFECTIONS NANOBIO CORPORATION 2010-03-25 — — US disclosed
WO-2009129470-A2 METHODS FOR TREATING HERPES VIRUS INFECTIONS NANOBIO CORPORATION (US) 2009-10-22 — — WO disclosed
US-6582947-B1 Nucleotide sequences coding enzymatic polypeptide for use in the virus treatment of cancer and viral infection BIO VICI (CH) 2003-06-24 — — US disclosed
EP-1137764-A1 NEW MEDICAL USE OF GENE AND VECTOR ENCODING A MULTISUBSTRATE DEOXYRIBONUCLEOSIDASE Biovici (CH) 2001-10-04 — — EP disclosed
WO-2000036099-A1 NEW MEDICAL USE OF GENE AND VECTOR ENCODING A MULTISUBSTRATE DEOXYRIBONUCLEOSIDASE BIOVICI (CH) 2000-06-22 — — WO disclosed
US-4990499-A Treatment of infections and neoplasms UNIVERSITY OF SASKATCHEWAN (CA) 1991-02-05 — — US disclosed
EP-0339161-A1 Novel fluorophosphonate nucleotide derivatives MERRELL DOW PHARMACEUTICALS INC. (US) 1989-11-02 — — EP disclosed
EP-0335770-A2 Novel fluorophosphonate nucleotide derivatives MERRELL PHARMACEUTICALS INC. (US) 1989-10-04 — — EP disclosed
US-4382925-A VIRICIDES, ESPECIALLY AGAINST HERPES VIRUS THE UNIVERSITY OF BIRMINGHAM (GB) 1983-05-10 — — US disclosed
US-4382925-A VIRICIDES, ESPECIALLY AGAINST HERPES VIRUS THE UNIVERSITY OF BIRMINGHAM (GB) 1983-05-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075914-A1 METHODS FOR TREATING HERPES VIRUS INFECTIONS STING1, IFNG, NGF TK1 18/4885CYP1A2 4640/4885CYP3A4 4587/4885
US-20130224268-A1 TOPICAL DELIVERY OF HORMONAL AND NON HORMONAL NANO FORMULATIONS, METHODS OF MAKING AND USING THE SAME SHBG, NR5A1, CYP19A1 TK1 3205/4885CYP1A2 666/4885CYP3A4 1522/4885
US-20120219602-A1 METHODS FOR TREATING HERPES VIRUS INFECTIONS STING1, IFNG, NGF TK1 18/4885CYP1A2 4640/4885CYP3A4 4587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.